New findings presented at ATS 2021 Conference also suggest novel test can be successfully enabled on nCounter Analysis System to support international expansion SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 14, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced that data reinforcing the
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 14, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced today new data demonstrating the ability of the Percepta ® Genomic Atlas to detect alterations that may inform lung cancer treatment decisions for patients from the same small biopsy that was used
Bonnie Anderson , Cofounder and CEO, to Assume Active Role as Executive Chairman; Marc Stapley to Become Chief Executive Officer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 10, 2021-- Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced its executive
Total Revenue of $36.7 Million Increased 18%; Volume Grew 11% to 14,437 Tests Completed Acquisition of Decipher Biosciences, Expanding Reach Into 7 of the Top 10 Cancers in the United States Pivotal Validation Data for Percepta Nasal Swab Lung Cancer Test To Be Presented at ASCO Conference Call and
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 4, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced today that new data relating to the Prosigna ® Breast Cancer Gene Signature Assay will be presented at the European Society of Medical Oncology (ESMO) Breast Cancer Virtual Congress 2021 taking
- Pivotal clinical validation data for Percepta Nasal Swab test in early lung cancer detection - - New data demonstrating ability of Decipher Prostate test to identify high metastasis risk in African American men - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 29, 2021-- Veracyte, Inc .
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 27, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced today the publication of a new study that demonstrates the robust performance of the Percepta Genomic Sequencing Classifier (GSC), a novel genomic test, in helping to improve lung cancer
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 20, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced today that it will release its full financial results for the first quarter of 2021 after the close of market on Monday, May 10 . Company management will host a conference call and webcast to
- New data support role of Percepta Genomic Atlas in genomic profiling for lung cancer patients – - Study suggests Envisia classifier can be successfully enabled on nCounter Analysis System - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 19, 2021-- Veracyte, Inc .
Keith Kennedy will retire following Q1 earnings release and 10-Q; Jane Alley appointed as acting CFO; Veracyte to conduct CFO search SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 15, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced that Keith Kennedy , chief financial officer and chief
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
